Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Total Liabilities (2023 - 2025)

Monte Rosa Therapeutics' Total Liabilities history spans 3 years, with the latest figure at $215.6 million for Q4 2025.

  • For Q4 2025, Total Liabilities changed 0.09% year-over-year to $215.6 million; the TTM value through Dec 2025 reached $215.6 million, changed 0.09%, while the annual FY2025 figure was $215.6 million, 0.09% changed from the prior year.
  • Total Liabilities reached $215.6 million in Q4 2025 per GLUE's latest filing, up from $214.0 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $215.8 million in Q4 2024 to a low of $65.0 million in Q2 2023.
  • Average Total Liabilities over 3 years is $126.7 million, with a median of $116.1 million recorded in 2024.
  • The largest YoY upside for Total Liabilities was 95.22% in 2025 against a maximum downside of 23.39% in 2025.
  • A 3-year view of Total Liabilities shows it stood at $124.5 million in 2023, then soared by 73.32% to $215.8 million in 2024, then fell by 0.09% to $215.6 million in 2025.
  • Per Business Quant, the three most recent readings for GLUE's Total Liabilities are $215.6 million (Q4 2025), $214.0 million (Q3 2025), and $91.5 million (Q2 2025).